Navigation Links
Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference
Date:5/24/2013

LOVELAND, Colo., May 24, 2013 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), a leading provider of veterinary diagnostic and specialty products, announced today that Dr. Robert Grieve , the Company's chairman and chief executive officer, and Jason Napolitano , executive vice president and chief financial officer, will present at the Second Annual Marcum MicroCap Conference, which is being held May 30, 2013 in New York City at the Grand Hyatt Hotel.

The Company's presentation is scheduled to begin at 1:30 p.m. EDT. The Heska group presentation will be available for the public to access via the Company's corporate website, www.heska.com at the time of the presentation and for two weeks thereafter. 

For more information and registration, please visit the conference website: http://www.marcumllp.com/microcap.

About Heska
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.  

About Marcum LLP
Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partner
'/>"/>

SOURCE Marcum LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Heska Announces Quarterly Dividend of $0.10 Per Share
2. Heska to Present at B. Riley Investor Conference
3. Heska Corporation Announces Amendment To Its Odd-Lot Tender Offer
4. Webcast Alert: Heska Announces Third Quarter 2012 Earnings Conference Call Webcast
5. Heska Enters Distribution Agreement with MWI Veterinary Supply
6. Heska Reports Third Quarter 2012 Earnings
7. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2012 Earnings Conference Call Webcast
8. Heska Announces 19.0% Revenue Growth for Fourth Quarter of Fiscal 2012
9. Webcast Alert: Heska Corporations Annual Meeting of Stockholders Webcast
10. Heska Corporation to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
11. Heska Corporation to Present at the 14th Annual B. Riley & Co. Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... N.J., Feb. 22, 2011 Covance Inc. (NYSE: ... 2nd Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 ... of the presentation at www.covance.com .  In order to ... minutes early. Covance, with headquarters in Princeton, New ...
... Telik, Inc. (Nasdaq: TELK ) reported a net loss ... ended December 31, 2010, compared with a net loss of $4.2 ...  For the year ended December 31, 2010, net loss was $24.7 ... $23.7 million, or $0.44 per share, for the year ended December ...
Cached Medicine Technology:Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 2Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 3Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 4Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 5
(Date:4/17/2014)... from LSTM have called for more research to ... in children in sub-Saharan Africa. In a paper ... Professor Russell Stothard, working with colleagues in the ... Reserve University, in Cleveland Ohio, University of Cambridge ... research into the joint burden of HIV/AIDS and ...
(Date:4/16/2014)... (April 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) ... study of CDX-1401 in solid tumors, including long-term patient ... (Vol 6 Issue 232). The data demonstrate robust ... benefit in patients with very advanced cancers and suggest ...
(Date:4/16/2014)... treatments are the leading cause of increases in multiple ... premature birth, these results are not inevitable, concludes an ... The article identifies six changes in policy and practice ... prematurity, including expanding insurance coverage for in vitro fertilization ...
(Date:4/15/2014)... CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... to fight invasive fungal infections, which kill about 1.5 million people ... action of amphotericin, an antifungal drug that has been in use ... as toxic to human cells as it is to the microbes ...
(Date:4/14/2014)... in chemotherapy over the past decade, but targeting drugs ... be a major challenge. , Nanotechnology has unlocked ... of nanocarriers, or capsules, that can transport cargoes of ... The catch? These carriers are tiny, and it matters ...
Breaking Medicine News(10 mins):Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Nano shake-up 2
... Cell-Based ... Melanoma Therapy, BOTHELL, Wash., ... developer and marketer of,proprietary hypothermic storage and cryopreservation media products for,cells, ... products in the cellular therapy and cord blood banking,market segments., ...
... Michelle Reesman, RN, Executive,Director, Passport Health Colorado, says far ... adventurous types, leave,home without taking the basic steps she ... preparation into their health as they do into their,destination ... 1) Get advice from a travel health ...
... LENEXA, Kan., Mar. 26 Mediware Information,Systems (Nasdaq: ... systems for,blood and medication management, has announced its ... hospital,blood banks and LifeTrak(R) software for blood centers, ... standards being required in the,United States., With ...
... for Voters on Health Care and,Social Security, ... said the most recent Medicare trustees, report calls ... issues.,According to the program,s trustees, Medicare,s Hospital Insurance ... Medicare must,rely also on interest accrued on trust ...
... 26 Spheris, a leading global,outsource provider of clinical ... and twelve months ended December 31, 2007., Financial ... fourth quarter of 2007 were $48.6 million compared,with $51.4 ... million decrease,in net revenues during the fourth quarter of ...
... a company,developing breakthrough molecular imaging agents for ... it has entered into a licensing,agreement with ... and,commercialization of agents for diagnosis and treatment ... were co-developed by,FluoroPharma and MGH scientists, target ...
Cached Medicine News:Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 2Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 3Health News:The Top Ten Health Tips for International Travel 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 3Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 4Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 5Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 6Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 7Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 8Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 9Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 10Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 11Health News:FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD) 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: